Alzheimer’s Benefits May Continue After Donanemab Treatment Ends, Data Suggest

(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease.
Early Alzheimer’s patients who completed their course…

Share this Post

More Posts

A ‘Ring Strategy’ for Bird Flu

(MedPage Today) — Six years after the COVID pandemic began, we are still locked in three of the five stages of a so-called typical response to a pandemic, as described in a recent opinion article. Those three stages are: Ignore and deny (stage…

Read More »
Hi, I’m SOPHie
Sophie Avatar SOPHie – Public Health Assistant
Powered by ChatGPT + Verified Sources